Previous 10 |
On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA ®, expected in Q3 2019 Assuming positive OPTIMAL data , NDA submission expected by year-end 2019 WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Chia...
Chiasma (NASDAQ: CHMA ) initiated with Overweight rating and $18 (208% upside) price target. Shares up 3% premarket. More news on: Chiasma, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, Read more ...
Thinly traded micro cap Chiasma ( CHMA +14.6% ) is up on almost a 6x surge in volume, albeit on turnover of only 374K shares. The stock has rallied 36% since last week. More news on: Chiasma, Healthcare stocks news, Stocks on the move, Read more ...
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that Mark Fitzpatrick, Chief Executive Officer and William Ludlam, MD...
WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of...
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of pat...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...